Blueprint Sales General And Administrative To Revenue from 2010 to 2024
BPMC Stock | USD 102.36 0.45 0.44% |
Sales General And Administrative To Revenue | First Reported 2010-12-31 | Previous Quarter 1.11573101 | Current Value 1.12 | Quarterly Volatility 0.30971107 |
Check Blueprint Medicines financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Blueprint main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.2 M, Interest Expense of 54.2 M or Selling General Administrative of 292.2 M, as well as many exotic indicators such as Price To Sales Ratio of 21.28, Dividend Yield of 0.0 or PTB Ratio of 44.91. Blueprint financial statements analysis is a perfect complement when working with Blueprint Medicines Valuation or Volatility modules.
Blueprint | Sales General And Administrative To Revenue |
Latest Blueprint Medicines' Sales General And Administrative To Revenue Growth Pattern
Below is the plot of the Sales General And Administrative To Revenue of Blueprint Medicines Corp over the last few years. It is Blueprint Medicines' Sales General And Administrative To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Blueprint Medicines' overall financial position and show how it may be relating to other accounts over time.
Sales General And Administrative To Revenue | 10 Years Trend |
|
Sales General And Administrative To Revenue |
Timeline |
Blueprint Sales General And Administrative To Revenue Regression Statistics
Arithmetic Mean | 1.11 | |
Geometric Mean | 1.03 | |
Coefficient Of Variation | 27.92 | |
Mean Deviation | 0.20 | |
Median | 1.27 | |
Standard Deviation | 0.31 | |
Sample Variance | 0.1 | |
Range | 1.2623 | |
R-Value | (0.33) | |
Mean Square Error | 0.09 | |
R-Squared | 0.11 | |
Significance | 0.23 | |
Slope | (0.02) | |
Total Sum of Squares | 1.34 |
Blueprint Sales General And Administrative To Revenue History
About Blueprint Medicines Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Blueprint Medicines income statement, its balance sheet, and the statement of cash flows. Blueprint Medicines investors use historical funamental indicators, such as Blueprint Medicines's Sales General And Administrative To Revenue, to determine how well the company is positioned to perform in the future. Although Blueprint Medicines investors may use each financial statement separately, they are all related. The changes in Blueprint Medicines's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Blueprint Medicines's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Blueprint Medicines Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Blueprint Medicines. Please read more on our technical analysis and fundamental analysis pages.
Last Reported | Projected for Next Year | ||
Sales General And Administrative To Revenue | 1.12 | 1.12 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out the analysis of Blueprint Medicines Correlation against competitors. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Blueprint Medicines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.82) | Revenue Per Share 4.632 | Quarterly Revenue Growth 0.519 | Return On Assets (0.24) | Return On Equity (0.80) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.